Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 9/20 | 0.33 |
| ▸ | POLQ | O75417 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23716448 | 0.92 | GPBAR1 (0.36) | GPBAR1POLQMLYCD | |
| SCHEMBL21563712 | 0.82 | RXFP1 (0.39) | POLQ | |
| SCHEMBL12348556 | 0.82 | GPBAR1 (0.38) | NR1H3NR1H2GPBAR1 | |
| SCHEMBL16986302 | 0.82 | NR1H3 (0.38) | NR1H3NR1H2GPBAR1TACR1 | |
| SCHEMBL16986375 | 0.81 | GPBAR1 (0.36) | NR1H3NR1H2GPBAR1 | |
| SCHEMBL23716793 | 0.80 | GAA (0.38) | — | |
| SCHEMBL12548396 | 0.80 | NR1H3 (0.38) | NR1H3NR1H2GPBAR1OPRM1 | |
| SCHEMBL12548126 | 0.80 | NR1H3 (0.38) | NR1H3NR1H2GPBAR1MLYCD | |
| SCHEMBL28992868 | 0.80 | GPBAR1 (0.36) | NR1H3NR1H2GPBAR1 | |
| SCHEMBL30266971 | 0.79 | GPBAR1 (0.35) | GPBAR1POLQMLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238126-A1 | Benzamide Compound and Use Thereof | METISA BIOTECHNOLOGY CO.,LTD. (CN) | 2021-08-05 | — | — | US | disclosed |
| WO-2019214588-A1 | BENZAMIDE COMPOUND AND APPLICATION THEREOF | 沈阳化工大学 (CN) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238126-A1 | Benzamide Compound and Use Thereof | TMBIM6, BCHE, DDT | NR1H3 3220/4885NR1H2 3146/4885GPBAR1 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.